View in EDS HTML Full Text PDF Full Text

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Authors: Kristensen, Lars Erik1 (AUTHOR) lars.erik.kristensen@regionh.dk, Keiserman, Mauro2 (AUTHOR), Papp, Kim3,4 (AUTHOR), McCasland, Leslie5 (AUTHOR), White, Douglas6,7 (AUTHOR), Carter, Kyle8 (AUTHOR), Lippe, Ralph8 (AUTHOR), Photowala, Huzefa8 (AUTHOR), Drogaris, Leonidas8 (AUTHOR), Soliman, Ahmed M.8 (AUTHOR), Chen, Michael8 (AUTHOR), Padilla, Byron8 (AUTHOR), Behrens, Frank9 (AUTHOR)
Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p617-632. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21986576
DOI:10.1007/s40744-024-00654-5